New Cholesterol Guidelines: Updated Standards for Heart Health

The American College of Cardiology (ACC), the American Heart Association (AHA), and nine other medical associations issued an updated guideline for the management of dyslipidemia on March 13, 2026. This comprehensive document replaces the 2018 guideline and provides a new evidence-based framework for assessing and treating abnormal levels of lipids and lipoproteins in the blood, including cholesterol and triglycerides.

The updated guidance emphasizes a shift toward lifelong prevention and earlier intervention to reduce the risk of atherosclerotic cardiovascular disease (ASCVD). ASCVD is caused by the buildup of fatty deposits in the arteries and remains the leading cause of death globally.

Prioritizing Earlier Intervention

A primary objective of the 2026 guidelines is to identify cardiovascular risk earlier in life. This approach reflects evidence that long-term exposure to elevated low-density lipoprotein (LDL) cholesterol—often referred to as bad cholesterol—drives the accumulation of arterial plaque over time.

According to the guidelines, treatment may begin as early as age 30 in some cases. This strategy aims to lower the lifetime exposure to unhealthy lipids, thereby reducing the long-term risk of heart attack and stroke.

The guidelines highlight that approximately 1 in 4 U.S. Adults have high levels of LDL-C, which underscores the necessity for earlier detection and proactive management.

New Assessment Tools and Target Goals

The updated recommendations introduce a new cardiovascular disease risk calculator known as Predicting Risk of Cardiovascular Disease EVENTs (PREVENT). This tool is designed to help clinicians better assess an individual’s risk profile to determine the most appropriate intervention strategy.

The guidance also reinforces lower LDL-C goals and recommends percent reductions based on an individual’s specific risk level. For individuals without existing cardiovascular disease, optimal LDL-C levels are considered to be below 100 mg/dL.

Beyond standard LDL-C testing, the guidelines suggest the selective use of additional diagnostic tools to refine risk assessment, including:

• Coronary calcium scoring
• Lipoprotein (a) testing
• Apolipoprotein B testing

Comprehensive Management Strategies

The 2026 guideline serves as a one-stop shop for the assessment and treatment of various blood lipids. It emphasizes a combination of healthy lifestyle habits and pharmacological intervention when recommended by a healthcare professional.

Key lifestyle recommendations included in the guidelines are:

• Maintaining a healthy weight
• Engaging in regular physical activity
• Avoiding tobacco products
• Prioritizing healthy sleep habits

The document was published simultaneously on March 13, 2026, in the flagship journals of the involved organizations: JACC, the journal of the American College of Cardiology, and Circulation, the journal of the American Heart Association.

Medical experts involved in the process, including those from NYU Langone Health’s Leon H. Charney Division of Cardiology, state that this shift toward more personalized and earlier treatment could significantly reduce the incidence of heart attacks and strokes over a patient’s lifetime.